Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin.

Alimentary pharmacology & therapeutics - 1 May 2008

Tang K H, Herrmann E, Pachiadakis I, Paulon E, Tatman N, Zeuzem S, Naoumov N V

Abstract excerpt

BACKGROUND: Individualized treatment regimens, taking into account the heterogeneity of patients with chronic hepatitis C, are needed to improve treatment outcomes. AIM: To investigate prospectively the period of undetectable viraemia required for a high rate of sustained virological response in patients with chronic hepatitis C genotype 1 and the relationship to early viral kinetics. METHODS: Forty-five chronic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Share to Statistics as Topic

Share to Viremia

Source

Identifiers

PMID: 18221408
DOI: 10.1111/j.1365-2036.2008.03628.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin.PMID 18221408Read ↗

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.Semantic proximity Read ↗

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.Semantic proximity Read ↗

Hepatitis C treatment: shorter and better?Semantic proximity Read ↗

Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3.Semantic proximity Read ↗

Hepatitis C treatment response kinetics and impact of baseline predictors.Semantic proximity Read ↗

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.Semantic proximity Read ↗

Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.Semantic proximity Read ↗

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?Semantic proximity Read ↗

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.Semantic proximity Read ↗

Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy.Semantic proximity Read ↗

Viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.